Literature DB >> 19719504

A nonsense SCN5A mutation associated with Brugada-type electrocardiogram and intraventricular conduction defects.

Kaveh Samani1, Tomohiko Ai, Jeffrey A Towbin, Ramon Brugada, Mossaab Shuraih, Yutao Xi, Geru Wu, Jie Cheng, Matteo Vatta.   

Abstract

Mutations of SCN5A, gene-encoding alpha-subunit of cardiac sodium channel, can cause mixed phenotypes of Brugada syndrome (BrS) and cardiac conduction diseases (CCD). We have identified a nucleotide change of SCN5A (4178T > G), which results in a nonsense mutation, L1393X, in a 36-year-old Caucasian man who presented with intraventricular conduction delays and BrS-type electrocardiogram change. To study biophysical characteristics of L1393X-SCN5A, electrophysiological and immuno-staining studies were performed using mammalian expression systems. While WT-SCN5A showed significant currents (93.3 +/- 10.6 pA/pF; 1 microg plasmid), L1393X (5 microg) did not generate any significant currents in NIH-3T3 cells. The cells cotransfected with WT (0.5 microg) and L1393X (0.5 microg) showed approximately 50% current amplitudes compared to the WT (1 microg). Voltage dependency of a steady-state activation and inactivation was not affected by the cotransfection of L1393X. Immuno-histochemical stainings demonstrated that L1393X proteins were expressed in the plasma membranes. Our study demonstrated that L1393X-SCN5A does not form functional channel proteins, which might account for the patient's mixed phenotypes of BrS and CCD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19719504      PMCID: PMC2747666          DOI: 10.1111/j.1540-8159.2009.02470.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  10 in total

Review 1.  Brugada syndrome: 1992-2002: a historical perspective.

Authors:  Charles Antzelevitch; Pedro Brugada; Josep Brugada; Ramon Brugada; Jeffrey A Towbin; Kolawanee Nademanee
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

2.  Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients.

Authors:  Jeroen P P Smits; Lars Eckardt; Vincent Probst; Connie R Bezzina; Jean Jacques Schott; Carol Ann Remme; Wilhelm Haverkamp; Günter Breithardt; Denis Escande; Eric Schulze-Bahr; Hervé LeMarec; Arthur A M Wilde
Journal:  J Am Coll Cardiol       Date:  2002-07-17       Impact factor: 24.094

3.  High risk for bradyarrhythmic complications in patients with Brugada syndrome caused by SCN5A gene mutations.

Authors:  Takeru Makiyama; Masaharu Akao; Keiko Tsuji; Takahiro Doi; Seiko Ohno; Kotoe Takenaka; Atsushi Kobori; Tomonori Ninomiya; Hidetada Yoshida; Makoto Takano; Naomasa Makita; Fumiko Yanagisawa; Yukei Higashi; Youichi Takeyama; Toru Kita; Minoru Horie
Journal:  J Am Coll Cardiol       Date:  2005-11-04       Impact factor: 24.094

4.  Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome.

Authors:  Matteo Vatta; Robert Dumaine; George Varghese; Todd A Richard; Wataru Shimizu; Naohiko Aihara; Koonlawee Nademanee; Ramon Brugada; Josep Brugada; Gumpanart Veerakul; Hua Li; Neil E Bowles; Pedro Brugada; Charles Antzelevitch; Jeffrey A Towbin
Journal:  Hum Mol Genet       Date:  2002-02-01       Impact factor: 6.150

5.  A mutant cardiac sodium channel with multiple biophysical defects associated with overlapping clinical features of Brugada syndrome and cardiac conduction disease.

Authors:  Nobumasa Shirai; Naomasa Makita; Koji Sasaki; Hisataka Yokoi; Ichiro Sakuma; Harumizu Sakurada; Jun Akai; Akinori Kimura; Masayasu Hiraoka; Akira Kitabatake
Journal:  Cardiovasc Res       Date:  2002-02-01       Impact factor: 10.787

6.  Progressive cardiac conduction defect is the prevailing phenotype in carriers of a Brugada syndrome SCN5A mutation.

Authors:  Vincent Probst; Marie Allouis; Frederic Sacher; Sabine Pattier; Dominique Babuty; Philipe Mabo; Jacques Mansourati; Jacques Victor; Jean-Michel Nguyen; Jean-Jacques Schott; Pierre Boisseau; Denis Escande; Hervé Le Marec
Journal:  J Cardiovasc Electrophysiol       Date:  2006-03

7.  Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family.

Authors:  F Kyndt; V Probst; F Potet; S Demolombe; J C Chevallier; I Baro; J P Moisan; P Boisseau; J J Schott; D Escande; H Le Marec
Journal:  Circulation       Date:  2001-12-18       Impact factor: 29.690

8.  A common SCN5A variant alters the responsiveness of human sodium channels to class I antiarrhythmic agents.

Authors:  Mossaab Shuraih; Tomohiko Ai; Matteo Vatta; Yoshiro Sohma; Eileen M Merkle; Erica Taylor; Zhaohui Li; Yutao Xi; Mehdi Razavi; Jeffrey A Towbin; Jie Cheng
Journal:  J Cardiovasc Electrophysiol       Date:  2007-01-10

9.  A novel nonsense mutation in the SCN5A gene leads to Brugada syndrome and a silent gene mutation carrier state.

Authors:  Dagmar I Keller; Fatima-Zahara Barrane; Laetitia Gouas; Johannie Martin; Sylvie Pilote; Vivian Suarez; Stefan Osswald; Marijke Brink; Pascale Guicheney; Nicola Schwick; Mohamed Chahine
Journal:  Can J Cardiol       Date:  2005-09       Impact factor: 5.223

10.  Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome: different incidences in familial and sporadic disease.

Authors:  Eric Schulze-Bahr; Lars Eckardt; Günter Breithardt; Karlheinz Seidl; Thomas Wichter; Christian Wolpert; Martin Borggrefe; Wilhelm Haverkamp
Journal:  Hum Mutat       Date:  2003-06       Impact factor: 4.878

  10 in total
  2 in total

Review 1.  The Mechanism of Ajmaline and Thus Brugada Syndrome: Not Only the Sodium Channel!

Authors:  Michelle M Monasky; Emanuele Micaglio; Sara D'Imperio; Carlo Pappone
Journal:  Front Cardiovasc Med       Date:  2021-12-23

2.  Phosphorylation of Lamin A/C at serine 22 modulates Nav 1.5 function.

Authors:  Michael A Olaopa; Tomohiko Ai; Bo Chao; Xiangshu Xiao; Matteo Vatta; Beth A Habecker
Journal:  Physiol Rep       Date:  2021-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.